Who is sponsoring NCT05504135?

NCT05504135 is sponsored by Nalagenetics Pte Ltd.

What drugs are being tested in NCT05504135?

Interventions in NCT05504135: Pharmacogenomics Testing.

What condition does NCT05504135 study?

NCT05504135 studies Pre-emptive Pharmacogenomics.

Is NCT05504135 still recruiting?

NCT05504135 is currently completed. Last updated 30 May 2025.

Last reviewed 2025-05-30 · How we verify

NCT05504135

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study)

Completed Last updated 30 May 2025

What this trial tests

trial testing Pharmacogenomics Testing in Pre-emptive Pharmacogenomics in 222 participants. Completed in 31 August 2024.

Timeline

3 October 2022

Primary endpoint
31 August 2023

31 August 2024

Quick facts

Lead sponsor	Nalagenetics Pte Ltd
Status	Completed
Study type	OBSERVATIONAL
Enrollment	222
Start date	3 October 2022
Primary completion	31 August 2023
Estimated completion	31 August 2024
Sites	1 location across Singapore

Drugs / interventions tested

Pharmacogenomics Testing

Conditions studied

Pre-emptive Pharmacogenomics — all drugs for Pre-emptive Pharmacogenomics →

Sponsor

Nalagenetics Pte Ltd — full company profile →

Who can join

Adults 21 to 65, any sex, with Pre-emptive Pharmacogenomics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In collaboration with Raffles Medical Group, we will be recruiting 500 patients and following them for the next 3-12 months to see whether pharmacogenomics information provided in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A feasibility study on implementing pre-emptive pharmacogenomics testing in outpatient clinics in Singapore (IMPT study).
Ng FF, Verma R, Sani L, Irwanto A, et al · · 2025 · cited 2× · PMID 40074758 · DOI 10.1038/s41397-025-00366-1

Verify or expand the search:

Other Nalagenetics Pte Ltd trials

Trials by the same sponsor.

NCT05562440 — The Perspective of Healthy Individuals on Breast Cancer Risk Prediction Report In The Indonesian Population · NA · completed
NCT05501158 — CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population · NA · unknown
NCT05570266 — Genetic and Non-Genetic Breast Cancer Risk Prediction Evaluation in Indonesian Samples · completed
NCT04312347 — Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05504135 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Nalagenetics Pte Ltd
Last refreshed: 30 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05504135.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing